NCT05284097View on ClinicalTrials.gov

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

March 2, 2023

Study Completion Date

October 31, 2024

Conditions
Virus DiseasesHemorrhagic Fever, EbolaInfectionsHemorrhagic Fevers, ViralRNA Virus InfectionsFiloviridae InfectionsMononegavirales InfectionsVaccinesImmunologic FactorsPhysiological Effects of DrugsEbola
Interventions
DRUG

Ad26.ZEBOV, MVA-BN-Filo

"Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant~MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus"

Trial Locations (1)

Unknown

EBOVAC Kambia 1 clinic, Kambia

All Listed Sponsors
collaborator

University of Sierra Leone

OTHER

collaborator

Janssen Vaccines & Prevention B.V.

INDUSTRY

lead

London School of Hygiene and Tropical Medicine

OTHER